---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-003922"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T02:54:45.660580+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bio-Path Holdings FY2024 net loss $9.9M; cash $1.2M; clinical progress in obesity and AML

## Summary
- Net loss of $9.9M ($4.12 per share) vs $16.1M ($33.63 per share) in FY2023.
- Cash and cash equivalents of $1.2M as of Dec 31, 2024; net cash used in operations $10.6M.
- R&D expense decreased to $7.3M from $11.6M; G&A expense increased to $4.7M.
- Preclinical BP1001-A shows restored insulin sensitivity; Phase 1/1b BP1002 in AML progressed to 90 mg/m² dose cohort.
- Patent portfolio expanded: 7 US patents, 61 foreign patents; new patents in US and NZ.

## SEC filing metadata
- accession: 0001558370-25-003922
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837025003922/0001558370-25-003922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837025003922/bpth-20250328x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-003922
- JSON: https://secwatch.observer/filing/0001558370-25-003922.json
- Plain text: https://secwatch.observer/filing/0001558370-25-003922.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.